Eli Lilly on tirzepatide data: Surpasses our expectations
During a teleconference on Tuesday, Eli Lilly stated that the pharmaceutical company has great expectations for the drug candidate tirzepatide against type 2 diabetes.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
US pharmaceutical company Eli Lilly has great expectations for the drug candidate tirzepatide now that results from the firm's Surpass program are in.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly lowers guidance for 2021
For subscribers
Eli Lilly has to wait a while longer for FDA verdict
For subscribers
EU politicians plan to focus on Europe's obesity problem
For subscribers
.jpg&w=384&q=75)
